<!DOCTYPE HTML>
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en-us">

  <head>
  <meta charset="utf-8">
  <meta http-equiv="X-UA-Compatible" content="IE=edge">
  <meta name="viewport" content="width=device-width, initial-scale=1">
  <meta name="description" content="AbRegen Pty Ltd is a preclinical stage biotechnology company that specialises in the development of antibody-based therapeutics for tissue repair applications.">
  <meta name="robots" content="index, follow">
  <meta name="apple-mobile-web-app-capable" content="yes">
  <meta http-equiv="X-UA-Compatible" content="IE=9" />

  <title>
    AbRegen Pty Ltd
  </title>

  <!-- CSS -->
  <link rel="stylesheet" href="/public/css/bootstrap.min.css">
  <link rel="stylesheet" href="/public/css/font-awesome.min.css">
  <link rel="stylesheet" href="/public/css/global.css">

  <!-- Icons -->
  <link rel="apple-touch-icon-precomposed" sizes="144x144" href="/public/apple-touch-icon-144-precomposed.png">
  <link rel="shortcut icon" href="/public/images/favicon.ico">

  <!-- Javascript -->
  <script type="text/javascript" src="/public/js/jquery.js"></script>
  <script type="text/javascript" src="/public/js/bootstrap.min.js"></script>
  
  
  

  <!-- RSS -->
  <link rel="alternate" type="application/rss+xml" title="RSS" href="/atom.xml">
</head>


  <body>

    <div class="navbar navbar-default" role="navigation">
      <div class="container-fluid">
        <div class="navbar-header">
          <button type="button" class="navbar-toggle" data-toggle="collapse" data-target=".navbar-collapse">
            <span class="sr-only">Toggle navigation</span>
            <span class="icon-bar"></span>
            <span class="icon-bar"></span>
            <span class="icon-bar"></span>
          </button>
          <a class="navbar-brand" href="/"><img src="/public/images/logo.png" /></a>
        </div>
        <div class="navbar-collapse collapse">
            <ul class="nav navbar-nav">
              
                
                  
                
                
                    <li class=""><a href="/">Home</a></li>
                
              
                
                  
                
                
                    <li class=""><a href="/board_and_management">Board and Management</a></li>
                
              
                 
                  
                
                
                  <li class="dropdown active">
                    <a href="" class="dropdown-toggle" data-toggle="dropdown">Technology<b class="caret"></b></a>
                    <ul class="dropdown-menu">
                      
                        <li><a href="/flightless_I">Flightless I</a></li>
                      
                        <li><a href="/publications">Publications</a></li>
                      
                    </ul>
                  </li>
                
              
                
                  
                
                
                    <li class=""><a href="/therapeutic_focus">Therapeutic Focus</a></li>
                
              
                
                  
                
                
                    <li class=""><a href="/news">News</a></li>
                
              
                
                  
                
                
                    <li class=""><a href="/contact">Contact</a></li>
                
              
            </ul>
        </div><!--/.nav-collapse -->
      </div>
    </div>


    
    <div class="container cp-content">
  <div class="cp-page-title">Flightless I</div>
  <p class="lead">

Flightless I (Flii) is a novel drug target that regulates important cellular behaviours including mobility, contraction, adhesion, proliferation and cytokine production. The activity of Flii is mediated through interaction with components of the cell’s cytoskeleton, modulation of intracellular signalling pathways and regulation of cellular transcription events. 

</p>

<div class="row">
	
	<div class="col-xs-8 col-sm-10 col-md-offset-2 col-md-4">
		
	  	<p class="lead">
	  		The <i>flightless I</i> gene was originally identified in <i>Drosophila melanogaster</i>, where mutations in the flightless I locus were found to cause flightlessness due to disordered indirect flight muscles (Campbell et al., (1993) PNAS 90 11386-11390).
		</p>
	</div>
	<div class="col-xs-4 col-sm-2 col-md-2 ">
		<img src="/public/images/drosophila.png" class="img-responsive img-thumbnail" alt="Responsive image">
		<!-- http://www.shutterstock.com/pic-11787406/stock-photo-microscopic-educational-a-female-drosophila-melanogaster-fruit-fly-whole-mount.html?src=_1_32GSla7H1LRRiiELLqg-1-37 -->
	</div>
</div>

<br/>


<p class="lead">
	A significant body of research has shown that Flii is a negative regulator of the migratory and proliferative events of tissue repair <a href="/publications">[see publications]</a>. For example, using transgenic models, it has been demonstrated that Flii ‘over-expressing’ mice exhibit larger, less contracted, wounds, reduced cellular proliferation and delayed reepithelialisation. Conversely, Flii-deficient mice show improved epidermal migration and re-epithelialisation, and enhanced wound vascularisation.
</p>

<p class="lead">
Importantly, neutralising antibodies to Flightless I have been shown to improve wound repair in murine and porcine models of normal and compromised would healing<sup>11, 17</sup>, and a murine model of epidermolysis bullosa<sup>15</sup>. 
</p>


<p class="lead">
	In addition, administration of anti-Flightless I antibodies reduces the incidence and growth of skin tumours in a mouse model of cutaneous squamous cell carcinoma (Kopecki et al., (2014) J Invest Dermatol 134:S28).
</p>

 


<br>

<div class="row">
	<div class="col-sm-12 col-md-8 col-md-offset-2">

		<h4 class="cp-graph-title">Treatment of early stage blisters with neutralising antibodies to Flightless I improves healing in a mouse model of epidermolysis bullosa</h4>

		<img src="/public/images/graph1.png" class="img-responsive img-thumbnail" alt="Responsive image">
	</div>
</div>

<br>


<p class="lead small-text">

Anti-flightless antibodies or IgG dose-matched control antibodies formulated in a cream vehicle were applied onto the skin of EB mice for three consecutive days at the start of blister formation (Days 8-10). EB mice treated with anti-flightless antibodies had significantly fewer blister lesions and lower histological blister scores compared with EB mice treated with control IgG antibody (Kopecki et al., 2012 J Invest Dermatol 133:1008-16).

</p>

<br>

<div class="row">
	<div class="col-sm-12 col-md-8 col-md-offset-2">

	<h4 class="cp-graph-title">Neutralising antibodies to Flightless I decrease skin tumour growth and severity.</h4>




		<img src="/public/images/graph2.png" class="img-responsive img-thumbnail" alt="Responsive image">
	</div>
</div>

<p class="lead small-text">

Anti-flightless antibodies or IgG dose-matched control antibodies were administered every two weeks (weeks, 0, 2, 4, 8) to primary squamous cell carcinomas induced on the back of Balb/c mice. Mice treated with anti-Flightless I had significantly decreased tumour volume from week 4.


</p>

</div>

   

     <!-- <div class="navbar navbar-default" role="navigation" style="padding-top:10px; margin-bottom:0;">
      <div class="container">
        <address>
          <strong>Twitter, Inc.</strong><br>
          795 Folsom Ave, Suite 600<br>
          San Francisco, CA 94107<br>
          <abbr title="Phone">P:</abbr> (123) 456-7890
        </address>

        <address>
          <strong>Full Name</strong><br>
          <a href="mailto:#">first.last@example.com</a>
        </address>
      </div>
    </div>
 -->
  <div class="container-fluid cp-footer">    
    <div class="row">
      <div class="col-sm-12">
          
            
              
            
            
               <div class="badge ">
                <a href="/">Home</a>
              </div>
              
            
            
              
            
            
               <div class="badge ">
                <a href="/board_and_management">Board and Management</a>
              </div>
              
            
             
              
            
            
              
              <div class="badge active">
                <a href="/flightless_I">Flightless I</a>
              </div>
              
              <div class="badge active">
                <a href="/publications">Publications</a>
              </div>
              
            
            
            
              
            
            
               <div class="badge ">
                <a href="/therapeutic_focus">Therapeutic Focus</a>
              </div>
              
            
            
              
            
            
               <div class="badge ">
                <a href="/news">News</a>
              </div>
              
            
            
              
            
            
               <div class="badge ">
                <a href="/contact">Contact</a>
              </div>
              
            
      </div>
    </div>
  </div>
  <div class="cp-copyright"> &copy; 2014 AbRegen Pty Ltd</div>

    


  </body>
</html>
